返回 
加入收藏
长、短效粒细胞刺激因子预防和治疗肺部恶性肿瘤化疗所致骨髓抑制的成本-效果分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 长、短效粒细胞刺激因子预防和治疗肺部恶性肿瘤化疗所致骨髓抑制的成本-效果分析 |
| TITLE： | |
| 摘要： | 目的：对比长、短效粒细胞刺激因子预防和治疗肺部恶性肿瘤化疗所致骨髓抑制的成本-效果，为临床合理用药提供参考。方法：回顾性分析郑州大学附属肿瘤医院2017年1月－2018年6月期间使用长、短效粒细胞刺激因子预防和治疗肺部恶性肿瘤化疗所致骨髓抑制的132例病例，其中使用重组人粒细胞刺激因子注射液（短效，A组）60例，使用聚乙二醇化重组人粒细胞刺激因子注射液（长效，B组）72例，比较两组患者的临床疗效、骨髓抑制情况、不良反应发生情况，计算两组治疗方案的成本，进行成本-效果分析，并以下调药品价格20％进行敏感性分析。结果：A、B组患者的总有效率分别为71.7％、75.0％，差异无统计学意义（P＞0.05），不同程度骨髓抑制情况的发生率和不良反应发生率差异也均无统计学意义（P＞0.05）；平均成本分别为（335.91±180.34）、（1 982.75±603.15）元，A组成本明显低于B组（P＜0.05），成本-效果比分别为4.69、26.44。以A组为参照，B组的增量成本-效果比为494.55。敏感性分析结果与成本-效果分析结果无差异。结论：重组人粒细胞刺激因子注射液和聚乙二醇化重组人粒细胞刺激因子注射液预防和治疗肺部恶性肿瘤化疗所致骨髓抑制的有效性相当，但前者的成本-效果比低于后者。 |
| ABSTRACT： | OBJECTIVE： To compare the cost-effectiveness of long-effect and short-effect granulocyte stimulating factor in prevention and treatment of bone marrow suppression induced by chemotherapy for lung malignancies， and to provide reference for rational drug use in the clinic. METHODS： A retrospective analysis was conducted for 132 cases who used granulocyte stimulating factor to prevent and treat bone marrow suppression induced by chemotherapy for lung malignancies in the Affiliated Tumor Hospital of Zhengzhou University during Jan. 2017 to Jun. 2018. Among them， 60 cases were treated with Recombinant human granulocyte stimulating factor injection （short-effect， group A）， and 72 cases were treated with Polyethylene glycol recombinant human granulocyte stimulating factor injection （long-effect， group B）. Clinical efficacies， the occurrence of bone marrow suppression and ADR were compared between 2 groups. Cost was calculated， and cost-effectiveness analysis was conducted. Sensitivity analysis was conducted by down-regulating 20％ drug price. RESULTS： The total response rates of group A and B were 71.7％ and 75.0％， without statistical significance （P＞0.05）. There was no statistical significance in the incidence and duration of bone marrow suppression or the incidence of ADR （P＞0.05）. Average treatment costs of the two groups were （335.91±180.34） and （1 982.75±603.15） yuan； the cost of group A was significantly lower than that of group B （P＜0.05）. The cost-effectiveness ratio of them were 4.69 and 26.44， while group A as a reference， incremental cost-effectiveness ratio of group B was 494.55. The sensitivity analysis results were in agreement with the cost-effectiveness analysis. CONCLUSIONS： The effectiveness of Recombinant human granulocyte stimulating factor injection is similar to that of Polyethylene glycol recombinant human granulocyte stimulating factor injection for the prevention and treatment of bone marrow suppression induced by chemotherapy for lung malignancies. But the cost-effectiveness ratio of the former is lower than that of the latter. |
| 期刊： | 2019年第30卷第13期 |
| 作者： | 张永娜，贺宝霞，张振鑫，陈金花，张文周 |
| AUTHORS： | ZHANG Yongna，HE Baoxia，ZHANG Zhenxin，CHEN Jinhua，ZHANG Wenzhou |
| 关键字： | 重组人粒细胞刺激因子注射液；聚乙二醇化重组人粒细胞刺激因子注射液；肺部恶性肿瘤；骨髓抑制；成本-效果分析 |
| KEYWORDS： | Recombinant human granulocyte stimulating factor injection； Polyethylene glycol recombinant human granulocyte stimulating factor injection； Lung malignancies； Bone marrow suppression； Cost-effectiveness analysis |
| 阅读数： | 672 次 |
| 本月下载数： | 17 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
